675 US Highway 1
North Brunswick, NJ 08902
Urigen Pharmaceuticals is a global leader in non-oncological urology treatments. As the baby boomer population ages there is a growing patient population. We specialize in developing innovative products to ameliorate the cause and symptoms associated with urological ailments, specifically Interstitial Cystitis/Bladder Pain Syndrome ("BPS" or "IC/BPS"). Urology represents a specialty pharmaceutical market of approximately 10,000 physicians in the United States. According to the American Urology Association (the "AUA"), urologists treat a variety of ailments of the urinary tract either surgically or medically. These include treating cancer, infections, stone disease, neurogenic bladder, overactive bladder, incontinence, prostate disease and IC/BPS. Many of these indications, we believe, represent significant, underserved therapeutic markets. We currently have one product candidate, URG101, in clinical development, and another product candidate, URG501, in pre-clinical development.
Who We Are
Urigen Pharmaceuticals' leadership is comprised of industry-leading management and world-renowned scientific advisors. Our team has decades of experience in Pharma business, commercial and product development. Collectively, we have planned and executed studies on numerous marketed and development compounds and our management did pioneering work in the field o f IC/BPS.
Dan Vickery, PhD, MBA
Director, COO and President Urigen Pharmaceuticals
Dr. Vickery’s experience includes senior corporate business and commercial development positions at Mylan Pharmaceuticals, Inc., and Pharmacia, Inc., and senior regulatory affairs positions at Kabi Pharmacia, Inc., and Warner-Lambert Inc. Dr. Vickery is an advisory board member of the Center for Molecular Medicine and Therapeutics, and on the Board of the Interstitial Cystitis Association. Dr. Vickery holds B.Sc. and Ph.D. degrees from the University of British Columbia, and earned an M.B.A. degree from the Richard Ivey School of Business, University of Western Ontario.
Lowell Parsons, MD
Chairman and Scientific Founder Urigen Pharmaceuticals
Dr. Parsons is a leader in medical research into the causes and treatment of interstitial cystitis, which is a BPS with typical cystoscopic and/or histological features in the absence of infection or other pathology, and has published over 200 scientific articles and book chapters in this area describing his work. Dr. Parsons received his M.D. degree from the Yale University School of Medicine in New Haven, CT, in 1970. After completing his medical internship at Yale in 1971, Dr. Parsons spent two years as a staff associate in the Laboratory of Microbiology at the National Institutes of Health in Bethesda, Maryland. He then completed his urology residency training at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, in 1977. Dr. Parsons joined the Division of Urology faculty at the University of California, San Diego, or UCSD, in 1977 as assistant professor. He served as Chief of Urology at the UCSD-affiliated Veterans Affairs Medical Center in La Jolla from 1977 to 1985. Since 1988, he has been Professor of Surgery/Urology at UCSD.
Abe Han, MBA
Mr. Han was previously a Principal in GLC Investment Advisors where he primarily focused on distressed investing and workouts. Prior to GLC Investment Advisors, Mr. Han was an Executive Director in UBS's Restructuring and Leveraged Finance Groups based in New York where he was responsible for the execution and structuring of restructuring, alternative capital, leveraged loan and high yield bond transactions. Prior to joining UBS, Mr. Han was the Steel Division Manager for Hyundai Corp. (USA). Mr. Han has served on Star Tribune's official unsecured creditors committee in bankruptcy and previously sat on PRC's Board of Directors representing the pre-petition 2nd lien lender class. Mr. Han holds a gaming license with the State of Pennsylvania. Mr. Han was selected by The M&A Advisor as one of the "40 Under 40". Mr. Han holds an MBA from Northwestern University and a BA degree from Rutgers University.
Carlo J. Di Fonzo, PhD
Dr. Di Fonzo leads drug development and regulatory affairs at Nektar with oversight responsibilities for regulatory affairs, GCP/GLP compliance and toxicology. Dr. Di Fonzo's experience includes over 25 years in regulatory affairs and safety roles in the pharmaceutical and biotechnology industry. During his career, Dr. Di Fonzo has been part of several teams that helped bring new medicines to patients, including Lipitor®, Neurontin®, Accupril®, Xigris®, Forteo®, Alimta®, Gemzar®, Zyprexa®, Strattera®, Cialis® and Movantik™. Prior to joining Nektar in 2006, Dr. Di Fonzo led regulatory affairs and quality compliance at Eli Lilly Canada, where he was also responsible for patent-listing strategies and product safety functions. Prior to joining Eli Lilly in November 2000, he worked at Warner-Lambert/Parke-Davis Canada, where he was had oversight of toxicology and safety studies as well as regulatory affairs. Dr. Di Fonzo received his undergraduate degree in biologic sciences, his master's degree in clinical biochemistry and his Ph.D. in clinical biochemistry and toxicology from the University of Toronto, Canada.